Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients

Highlights

• Nearly one-third (33%) of patients with relapsed/refractory multiple myeloma (RRMM) achieved ≥5 years of progression-free survival (PFS) after a single cilta-cel infusion.
• Long-term survivors showed specific biomarker profiles, including lower tumor burden and higher effector-to-target (E:T) cell ratios.
• Cilta-cel maintained a consistent safety profile, with no new long-term safety signals identified over five years of follow-up.
• This result challenges historical expectations for RRMM, where median PFS is typically less than six months, and median overall survival (OS) is about a year.

Clinical Background and Disease Burden